Novonesis in the news

Australia's competition watchdog is reviewing Novonesis' proposed acquisition of Microbiogen.

SEB increased Novonesis's price target to 560 Danish kroner and reiterated its buy rating.

Novonesis's Dr. Steve Lerner explains how improving feed efficiency, gut health, and microbiome management can enhance poultry production efficiency and sustainability.

Novonesis increased its 2026 outlook due to an 8% jump in first-half sales, alongside announcing a EUR 1 billion share buyback program and acquiring the remaining 77% of MicroBioGen.

Novonesis shares jumped 9% due to strong Q2 results, raised 2026 sales guidance, and the announcement of a —1 billion share buyback program.

Novonesis will host a webinar presenting new clinical findings and ESPGHAN highlights on Human Milk Oligosaccharides (HMOs), featuring research from their experts and academic collaborations.

Novonesis stock rose after an improved financial forecast and the announcement of a ‑1 billion share buyback program.

Novonesis's CEO highlighted strong half-year earnings and the company's use of AI to accelerate R&D.

Novonesis expects 2027 results from a study with Novo Nordisk on microbiome supplements improving GLP-1 weight-loss drug benefits.

Novonesis reported strong first-half results, raising its full-year organic growth and EBITDA margin outlook, alongside announcing a share buyback and an acquisition.

Morgan Stanley increased its price target for Novonesis to 535 Danish kroner and maintained an overweight rating.

Novonesis expects study results for its weight-loss drug supplement in 2027.

Novonesis shares surged after the company raised its financial forecast and announced a €1 billion share buyback program.

Novonesis's shares led the Stoxx 600 after reporting strong sales growth and raising its guidance.

Novonesis's H1 2026 results show 8% organic sales growth, prompting a raised full-year outlook and the announcement of a 1 billion euro share buyback program.

Novonesis approved a EUR 1 billion share buyback program to start in H2 2026.

Novonesis projects its adjusted EBITDA margin for the fiscal year to be 37-38%.

DNB Carnegie has raised Novonesis's target price to 470 Danish kroner from 450, maintaining a buy rating.

Novonesis reported strong 8% organic sales growth in H1 2026, increased its full-year outlook, and announced a EUR 1 billion share buyback program.

Novonesis plans a ₹3,000-crore investment in Maharashtra over the next two to three years to expand manufacturing for biofuels, food, health, and agricultural biologicals.